Top evidence (RCT only, high risk of bias excluded)
Best available evidence (possibly low or very low)
All RCTs
All studies (RCT+OBS)
studies
breast cancer (BC), buparlisib based treatment vs. all, meta-analysis of study results Outcome TE 95% CI n k I2 ROB Pub. bias deaths (OS)detailed results BELLE-2 (full population), 2017 0.87 [0.74; 1.02]
BELLE-2 (patients with known PI3K status), 2017 0.91 [0.75; 1.10]
0.89 [0.79 ; 1.00 ] BELLE-2 (full population), 2017, BELLE-2 (patients with known PI3K status), 2017 2 0% 1,998 low not evaluable progression or deaths (PFS)detailed results BELLE-2 (full population), 2017 0.78 [0.68; 0.90]
BELLE-2 (patients with known PI3K status), 2017 0.80 [0.68; 0.94]
BELLE-2 (PI3K pathway activated), 2017 0.76 [0.60; 0.97]
0.78 [0.71 ; 0.86 ] BELLE-2 (full population), 2017, BELLE-2 (patients with known PI3K status), 2017, BELLE-2 (PI3K pathway activated), 2017 3 0% 2,370 low not evaluable objective responses (ORR)detailed results BELLE-2 (full population), 2017 1.60 [1.08; 2.39]
BELLE-2 (patients with known PI3K status), 2017 1.47 [0.92; 2.34]
BELLE-2 (PI3K pathway activated), 2017 1.34 [0.66; 2.71]
1.51 [1.14 ; 1.99 ] BELLE-2 (full population), 2017, BELLE-2 (patients with known PI3K status), 2017, BELLE-2 (PI3K pathway activated), 2017 3 0% 2,370 low not evaluable 0.5 2.0 1.0 relative treatment effect www.metaEvidence.org 2024-09-27 17:18 +02:00
TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers);
k: number of studies; n: total number of patients;
ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1;
studied treatment is better when TE < 1;
pathologies: 64,370,336,147,145,355,337,146,317,4,319,144,356,351,357,352,354,353,358,359,324,142,305,306,98,96,269,60,143,270,140,240,3
- treatments: 1430,1360,1431